SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
SECURITIES AND EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 10, 2004
GERON CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 0-20859 75-2287752
(State or Other (Commission File Number) (IRS Employer
Jurisdiction Identification Number)
of Incorporation)
230 Constitution Drive 94025
Menlo Park, California (Zip Code)
(Address of principal executive offices)
(650) 473-7700
(Registrant's telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
On March 10, 2004, Geron Corporation, a Delaware corporation (the "Company") and
Merix Bioscience, Inc., a Delaware corporation ("Merix") announced that the
companies have executed an agreement (the "Agreement") under which the Company
has acquired a license under Merix's platform technology, including the
exclusive right to use the platform technology in therapeutic cancer vaccines
using the enzyme telomerase as an antigen.
The Company's press release announcing the Agreement is filed as an exhibit to
this Current Report on Form 8-K. The summary description of the transaction and
the press release are qualified in their entirety by reference to the document
filed as an exhibit hereto.
Item 7. Exhibits.
Exhibits
99.1 Press Release dated March 10, 2004
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GERON CORPORATION
Date: March 10, 2004 By: /s/ William D. Stempel
----------------------------------
Name: William D. Stempel
Title: Vice President and General Counsel
EXHIBIT INDEX
Exhibits
--------
99.1 Press Release dated March 10, 2004
3